AbCellera Biologics (NASDAQ:ABCL) Upgraded at Leerink Partnrs

AbCellera Biologics (NASDAQ:ABCL - Get Free Report) was upgraded by equities researchers at Leerink Partnrs to a "strong-buy" rating in a research note issued on Monday,Zacks.com reports. Leerink Partnrs also issued estimates for AbCellera Biologics' Q2 2025 earnings at ($0.16) EPS, Q3 2025 earnings at ($0.16) EPS, Q4 2025 earnings at ($0.16) EPS, FY2025 earnings at ($0.64) EPS and FY2026 earnings at ($0.28) EPS.

ABCL has been the subject of several other reports. KeyCorp lifted their target price on AbCellera Biologics from $4.00 to $5.00 and gave the company an "overweight" rating in a research report on Wednesday, April 16th. Truist Financial lowered their price objective on shares of AbCellera Biologics from $28.00 to $10.00 and set a "buy" rating for the company in a research note on Friday, May 16th. Finally, Leerink Partners initiated coverage on shares of AbCellera Biologics in a research note on Monday. They set an "outperform" rating and a $5.00 target price on the stock. One investment analyst has rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, AbCellera Biologics has an average rating of "Buy" and a consensus target price of $7.50.

AbCellera Biologics Price Performance

Shares of ABCL stock traded down $0.24 during trading hours on Monday, hitting $4.01. The company had a trading volume of 5,616,222 shares, compared to its average volume of 3,487,406. The stock has a market capitalization of $1.20 billion, a PE ratio of -7.16 and a beta of 0.62. The company's fifty day moving average is $2.82 and its 200 day moving average is $2.76. AbCellera Biologics has a fifty-two week low of $1.89 and a fifty-two week high of $4.33.

AbCellera Biologics (NASDAQ:ABCL - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.15) EPS for the quarter, topping analysts' consensus estimates of ($0.17) by $0.02. AbCellera Biologics had a negative return on equity of 15.98% and a negative net margin of 737.56%. The company had revenue of $4.24 million for the quarter, compared to analysts' expectations of $7.12 million. Equities analysts forecast that AbCellera Biologics will post -0.59 earnings per share for the current year.

Institutional Trading of AbCellera Biologics

A number of large investors have recently made changes to their positions in ABCL. Stratos Wealth Advisors LLC purchased a new stake in shares of AbCellera Biologics in the 1st quarter valued at approximately $27,000. DKM Wealth Management Inc. purchased a new position in AbCellera Biologics in the fourth quarter valued at $29,000. Janney Montgomery Scott LLC purchased a new position in AbCellera Biologics in the first quarter valued at $29,000. AssuredPartners Investment Advisors LLC acquired a new stake in AbCellera Biologics in the first quarter valued at $34,000. Finally, Balyasny Asset Management L.P. purchased a new stake in AbCellera Biologics during the 4th quarter worth about $40,000. 61.42% of the stock is currently owned by hedge funds and other institutional investors.

AbCellera Biologics Company Profile

AbCellera Biologics Inc builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis.